CompletedNot Applicable

Post-License Safety Evaluation of Influenza Virus Vaccine

400,000 participantsStarted 2013-01

Plain-language summary

To evaluate the safety of the post-licensed influenza virus vaccine made of Changchun Institute of Biological Products Co.,Ltd.

Who can participate

Age range3 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ever vaccinated one dose influenza vaccine(manufactured by Changchun institute of biological product) in 2013 * above 3 years old Exclusion Criteria: * Severe allergic reaction (e.g., anaphylaxis) after previous dose of any IIV or LAIV * allergic to a vaccine component, including egg protein.

What they're measuring

occurence rate of adverse reaction

Timeframe: 1 month after vaccination

Trial details

NCT IDNCT02136017

SponsorSichuan Center for Disease Control and Prevention

Sponsor typeOTHER_GOV

Study typeOBSERVATIONAL

Primary completion2013-12

View on ClinicalTrials.gov More Influenza trials